Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients

CompletedOBSERVATIONAL
Enrollment

1,018

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

September 5, 2025

Study Completion Date

September 5, 2025

Conditions
Ovarian CancerProstate Cancer
Trial Locations (37)

Unknown

Research Site, Anhui

Research Site, Beijing

Research Site, Changsha

Research Site, Chengdu

Research Site, Chongqing

Research Site, Dongguan

Research Site, Foshan

Research Site, Fujian

Research Site, Guangdong

Research Site, Guangzhou

Research Site, Guangzho

Research Site, Guizhou

Research Site, Hangzhou

Research Site, He'nan

Research Site, Hebei

Research Site, Heilongjiang

Research Site, Henan

Research Site, Huizhou

Research Site, Jiangsu

Research Site, Jiangxi

Research Site, Jilin

Research Site, Jinghou

Research Site, Liaoning

Research Site, Luzhou

Research Site, Nanjing

Research Site, Nantong

Research Site, Ningbo

Research Site, Shandong

Research Site, Shanghai

Research Site, Shenyang

Research Site, Sichuan

Research Site, Taiyuan

Research Site, Tianjin

Research Site, Yichang

Research Site, Yunan

Research Site, Zhejiang

Research Site, Zhengzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY